Mathers Edward T 4

What Happened
Edward T. Mathers, a director of Rhythm Pharmaceuticals (RYTM), acquired 4,199 shares of the company's common stock on March 12, 2026. The shares were received at no cost (reported price $0.00) as a pro rata distribution from NEA Partners 13; total cash value reported for the transaction is $0. This is an acquisition by distribution from an investor vehicle, not an open-market purchase.

Key Details

• Transaction date and type: 2026-03-12 — "Other acquisition or disposition" (Form 4 code J), 4,199 shares acquired at $0.00.
• Filing date: Form 4 filed 2026-03-16 — appears timely (filed within the required reporting window).
• Shares owned after transaction: not specified in the provided excerpt; the Mathers Trust is reported as the direct beneficial owner of the distributed shares.
• Notable footnotes: (F1) NEA Partners 13 made a pro rata distribution for no consideration to its limited partners; the Edward Timothy Mathers Revocable Trust received 4,199 shares. (F2) Edward Mathers is the trustee of the Mathers Trust and disclaims beneficial ownership of trust holdings in which he has no pecuniary interest.

Context
This was a distribution of shares from a fund to limited partners (a non-market transfer), which does not necessarily signal insider sentiment about the company’s prospects. The reporting person is acting as trustee; the mechanics reflect a pass-through distribution from an investor vehicle rather than a personal purchase or sale.